ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2017
Surveillance perspective on Lyme borreliosis across the European Union and European Economic Area.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Seroprevalence of Lyme Borreliosis in Europe: Results from a Systematic Literature Review (2005-2020).Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2023Pooled it
- Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005-2020).Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2023Pooled it
- Incidence of Lyme Borreliosis in Europe: A Systematic Review (2005-2020).Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2023Pooled it
- Review
- One Health tick bite exposure biomarkers against Ixodes ricinus salivary peptides.Research square · 2026Article
- A lipid compendium of a metabolically compromised bacterium provides insights into lipid acquisition, biosynthesis, and metabolism.bioRxiv : the preprint server for biology · 2026Article
- Performance of the French national hospital discharge database algorithm to identify hospitalised Lyme borreliosis cases, France, 2017-2018.BMC infectious diseases · 2026Article
- Consultations in general practice related to a tick bite episode in mainland France in 2023-2024.BMC public health · 2026Article
- Antibodies against tick-borne pathogens in domestic dogs in Norway: Borrelia burgdorferi sensu lato, tick-borne encephalitis virus, and Anaplasma phagocytophilum.Acta veterinaria Scandinavica · 2026Article
- Experience of a Romanian Lyme Borreliosis Centre in the Multidisciplinary Management of Patients Evaluated for Suspected Lyme Neuroborreliosis.Microorganisms · 2026Article
- Running into the Lyme-light: a retrospective cross-sectional study of tick bites and Lyme disease prevalence, incidence, and prevention in hill runners, Scotland, UK.BMC public health · 2026Article
- Silent Spread ofHealthcare (Basel, Switzerland) · 2025Article
- Lyme Borreliosis Incidence Across Europe, 2015-2023: A Surveillance-Based Review and Analysis.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2025Review
- A Lyme disease mRNA vaccine targetingMolecular therapy. Nucleic acids · 2025Article
- Modelling the impact of climate and the environment on the spatiotemporal dynamics of Lyme borreliosis in Germany.EBioMedicine · 2025Article
- Article
- Twenty Years of Lyme Borreliosis in the Netherlands: Temporal Trends in Seroprevalence and Risk Factors.Microorganisms · 2024Article
- Incidence of symptomatic Borrelia burgdorferi sensu lato infection in Romania, 2018-2023.Parasites & vectors · 2024Article
- The Role of Environmental Factors in Lyme Disease Transmission in the European Union: A Systematic Review.Tropical medicine and infectious disease · 2024Review
- Why Is the Duration of Erythema Migrans at Diagnosis Longer in Patients with Lyme Neuroborreliosis Than in Those without Neurologic Involvement?Pathogens (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lyme borreliosis (LB) is the most prevalent tick-borne disease in Europe. Erythema migrans (EM), an early, localised skin rash, is its most common presentation. Dissemination of the bacteria can lead to more severe manifestations including skin, neurological, cardiac, musculoskeletal and ocular manifestations. Comparison of LB incidence rates in the European Union (EU)/European Economic Area (EEA) and Balkan countries are difficult in the absence of standardised surveillance and reporting procedures. We explored six surveillance scenarios for LB surveillance in the EU/EEA, based on the following key indicators: (i) erythema migrans, (ii) neuroborreliosis, (iii) all human LB manifestations, (iv) seroprevalence, (v) tick bites, and (vi) infected ticks and reservoir hosts. In our opinion, neuroborreliosis seems most feasible and useful as the standard key indicator, being one of the most frequent severe LB manifestations, with the possibility of a specific case definition. Additional surveillance with erythema migrans as key indicator would add value to the surveillance of neuroborreliosis and lead to a more complete picture of LB epidemiology in the EU/EEA. The other scenarios have less value as a basis for EU-level surveillance, but can be considered periodically and locally, as they could supply complementary insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.